This article was published on July 10, 2022. It was last updated on July 11, 2022. Semaglutide injection (Wegovy™) is a glucagon-like peptide-1 (GLP-1) receptor agonist that is given as a once-weekly subcutaneous injection for “chronic weight management” in specified subgroups of patients (see FDA indications below). It was approved by the FDA in 2021…
This content is for Monthly Membership and Yearly Membership members only.
Register
Register
Already a member? Log in here